Risk and Protective Factors for Gastrointestinal Symptoms associated with Antibiotic Treatment in Children: A Population Study
10.5223/pghn.2020.23.1.35
- Author:
Mario BAÙ
1
;
Alex MORETTI
;
Elisabetta BERTONI
;
Valentino VAZZOLER
;
Chiara LUINI
;
Massimo AGOSTI
;
Silvia SALVATORE
Author Information
1. Department of Pediatric, Ospedale “F. Del Ponte”, University of Insubria, Varese, Italy. silvia.salvatore@uninsubria.it
- Publication Type:Original Article
- Keywords:
Abdominal pain;
Anti-bacterial agents;
Antibiotic-associated diarrhea;
Children;
Constipation;
Diarrhea;
Lactobacillus reuteri;
Lactobacillus rhamnosus GG;
Probiotics
- MeSH:
Abdominal Pain;
Administration, Intravenous;
Anti-Bacterial Agents;
Child;
Constipation;
Diarrhea;
Humans;
Incidence;
Inpatients;
Lactobacillus reuteri;
Lactobacillus rhamnosus;
Probiotics;
Prospective Studies;
Protective Factors;
Urinary Tract Infections
- From:Pediatric Gastroenterology, Hepatology & Nutrition
2020;23(1):35-48
- CountryRepublic of Korea
- Language:English
-
Abstract:
6 years (RR=4.15), with previous abdominal pain (RR=7.2) or constipation (RR=4.06). Constipation was recorded in 23/289 (8.0%), with increased risk in children having surgery (RR=2.56) or previous constipation (RR=7.38). Probiotic supplementation significantly reduced AAD (RR=0.30) and abdominal pain (RR=0.36). Lactobacillus rhamnosus GG (LGG) and L. reuteri significantly reduced AAD (RR=0.37 and 0.35) and abdominal pain (RR=0.37 and 0.24).CONCLUSION: AAD occurred in 20.4% of children, with increased risk at younger age, lower respiratory and urinary tract infections, intravenous treatment and previous AAD. LGG and L. reuteri reduced both AAD and associated abdominal pain.]]>
